Definium Therapeutics (NASDAQ:DFTX) Issues Earnings Results

Definium Therapeutics (NASDAQ:DFTX) issued its quarterly earnings data on Thursday. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• Three pivotal DT120 ODT phase III readouts are imminent — EMERGE (MDD) top-line later this quarter, and VOYAGE and PANORAMA (both GAD) expected in early and late Q3 respectively, with Breakthrough Therapy designation for DT120 in GAD and an NDA submission planned subject to positive data.
• All pivotal trials are near complete (EMERGE 149 enrolled; VOYAGE 214; PANORAMA >200) and were powered around a 5‑point placebo‑adjusted difference (VOYAGE/PANORAMA >99% power; EMERGE 80% with ~3‑point significance threshold), which management says targets clinically meaningful and durable single‑dose effects.
• Each study includes a Part B with up to one year of follow‑up and up to four open‑label retreatments triggered at moderate symptoms, intended to characterize retreatment patterns, durability, and longer‑term safety for potential labeling discussions.
• The company ended Q1 with $373.4 million in cash and investments, which management believes provides runway to fund planned operations through multiple pivotal readouts and into 2028.
• Near‑term spend ramped materially — Q1 R&D rose to $41.5M and G&A to $17.7M versus prior year — contributing to a wider net loss of $77.1M, with a $20M quarterly impact from warrant fair‑value movement, indicating higher cash burn and elevated execution costs ahead.

Definium Therapeutics Stock Down 5.0%

DFTX stock traded down $1.15 during trading on Friday, hitting $22.05. 2,203,452 shares of the stock traded hands, compared to its average volume of 1,963,772. Definium Therapeutics has a 1 year low of $6.03 and a 1 year high of $26.25. The firm’s 50 day moving average is $19.98 and its two-hundred day moving average is $16.05. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -8.86 and a beta of 2.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29.

Institutional Trading of Definium Therapeutics

Several institutional investors have recently bought and sold shares of the company. Commodore Capital LP grew its position in Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after purchasing an additional 475,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Definium Therapeutics by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after acquiring an additional 198,878 shares during the last quarter. UBS Group AG boosted its holdings in shares of Definium Therapeutics by 7.3% during the 3rd quarter. UBS Group AG now owns 551,809 shares of the company’s stock valued at $6,506,000 after acquiring an additional 37,364 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Definium Therapeutics during the 3rd quarter valued at about $4,337,000. Finally, Millennium Management LLC boosted its holdings in shares of Definium Therapeutics by 62.6% during the 3rd quarter. Millennium Management LLC now owns 298,205 shares of the company’s stock valued at $3,516,000 after acquiring an additional 114,805 shares during the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DFTX. Stifel Nicolaus set a $30.00 target price on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Thursday, April 16th. Leerink Partners upped their target price on shares of Definium Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a research report on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Definium Therapeutics in a research report on Thursday, April 23rd. Finally, Wolfe Research initiated coverage on shares of Definium Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $37.92.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.